Search Results

Thermedical®, a developer of advanced thermal-ablation systems to treat ventricular arrhythmias, announced today that it has completed a feasibility study utilizing Pulsed Field Ablation (PFA) therapy in combination with its SERF Ablation System and Durablate® Catheter for treating ventricular tachycardia (VT).

Thermedical®, a developer of thermal-ablation systems to treat ventricular arrhythmias, announced it has received $3 million in grant funding from the National Heart, Lung, and Blood Institute, a part of the National Institutes of Health, to fund its FDA-approved clinical trial at seven centers in the U.S. and Canada using the SERF Ablation System with the Durablate® Catheter to treat ventricular tachycardia.

Thermedical®, a developer of thermal-ablation systems to treat ventricular arrhythmias, announced today that the U.S. Food & Drug Administration (FDA) has approved an open-label, single-arm interventional clinical trial to evaluate the safety and efficacy of the Thermedical® SERF Ablation System with the Durablate® Catheter in people with ventricular tachycardia (VT) resistant to conventional treatment.

The Montreal Heart Institute (MHI) and Thermedical ® , a developer of thermal-ablation systems to treat ventricular arrhythmias, today announced the first ablation performed using the groundbreaking Durablate® retractable needle catheter and degassed saline, which together eliminate over 98% of

The Montreal Heart Institute (MHI) and Thermedical ® , a developer of thermal-ablation systems to treat ventricular arrhythmias, today announced the first ablation performed using the groundbreaking Durablate® retractable needle catheter and degassed saline, which together eliminate over 98% of the air bubbles that can lead to stroke. Health Canada and the U.S. Food & Drug Administration (FDA) approved Thermedical’s

Thermedical ® , a developer of thermal-ablation medical systems to treat ventricular tachycardia (VT), today announced that it has received Breakthrough Device Designation from the U.S. Food & Drug Administration (FDA) for its Saline Enhanced Radiofrequency (SERF) Ablation system and Durablate® catheter. The FDA Breakthrough Devices Program is intended to help patients receive more timely access to technologies tha

Thermedical® announced that Roy T. Tanaka has been appointed to the company’s board of directors.

Results Suggest Highly Effective Method to Treat Ventricular Tachycardia, a Leading Cause of Sudden Cardiac Death

The single-arm, observational study is designed to evaluate the safety and effectiveness of the Durablate catheter to treat ventricular tachycardia